Skip to main content

Anti-Rheumatic Rx

      “We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review

      She told us sh

      David Liew drdavidliew

      6 days 14 hours ago
      “We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review She told us she is speaking about diseases outside her comfort zone but she is bang on. As she said: not good enough real world all the people not on steroid-sparing Rx @RheumNow https://t.co/4WiEORwPgI
      Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?

      I

      David Liew drdavidliew

      6 days 16 hours ago
      Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy? Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2 Very decent on primary (ESSDAI) & we will see this Salivary flow only improved when some at baseline #ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
      Effectiveness of b/tsDMARDs RA pts kidney dysfunction

      CorEvitas RA registry 9,569 pts
      Pts low eGFR = older more comorbi

      Aurelie Najm AurelieRheumo

      6 days 16 hours ago
      Effectiveness of b/tsDMARDs RA pts kidney dysfunction CorEvitas RA registry 9,569 pts Pts low eGFR = older more comorbidities less NSAIDs Reduced eGFR = 30% less likely to achieve remission Persists indeed of GC intake Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg
      b/tsDMARD in RA + CKD (eGFR <60)

      From >12K pts in CorEvitas:
      - overall effective but 30% ↓ CDAI-emission (HR 0.

      Jiha Lee JihaRheum

      6 days 16 hours ago
      b/tsDMARD in RA + CKD (eGFR <60) From >12K pts in CorEvitas: - overall effective but 30% ↓ CDAI-emission (HR 0.71) - Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi @RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA
      Day 3 in Chicago is hump day, the last big full day of presentations and posters.  The day began with an 8AM plenary session, which brings me to the first of my three notables from today:
      We often see patients with MTX lab abnormalities but How frequent is MTX toxicity?

      Retrospective study 2500pts
      Rocheste

      Aurelie Najm AurelieRheumo

      1 week ago
      We often see patients with MTX lab abnormalities but How frequent is MTX toxicity? Retrospective study 2500pts Rochester Epidemiology Project cohort 60% w/ ever lab abnormalities, but 4% attributed to MTX 0.87/100 patient year Organ injury event 0.02/100 patient year = 5 in https://t.co/w8oYUjj5Yp
      Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.
      Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.  Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.
      At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
      DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario co

      David Liew drdavidliew

      1 week ago
      DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort. We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful #ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
      Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rh

      Bella Mehta bella_mehta

      1 week ago
      Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases. Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7
      Predictors of retinopathy progression after HCQ discontinued?

      In the chart review of 28 pt records who had retinopathy,

      sheila RHEUMarampa

      1 week ago
      Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
      There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but th

      David Liew drdavidliew

      1 week ago
      There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside… Beware+++ #ACR25 FDA Update @RheumNow https://t.co/rco4wTXBjO
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is no

      David Liew drdavidliew

      1 week ago
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
      ×